| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA350: Secukinumab for treating moderate to severe plaque psoriasis |
|
Medicine details |
|
| Medicine name | secukinumab (Cosentyx®) |
| Formulation | 150 mg powder for solution for injection |
| Reference number | 1306 |
| Indication | Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy |
| Company | Novartis Pharmaceuticals UK Ltd |
| BNF chapter | Skin |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 19/02/2015 |
| NICE guidance | TA350: Secukinumab for treating moderate to severe plaque psoriasis |